KEY DETAILS
A lawsuit claims Novo Nordisk misled patients about Ozempic's weight loss benefits and hid safety risks, with the case still ongoing.
A separate lawsuit over Novo Nordisk's GLP-1 pricing and marketing is moving through court, and the outcome could affect drug costs.
Eli Lilly faces a lawsuit accusing it of breaking marketing rules for GLP-1 drugs, which could lead to label changes or settlements.
Eli Lilly is testing orforglipron in 2,000 overweight adults to see if it can prevent diabetes and obesity progression.
A new injectable GLP-1 drug, zovaglutide, is being tested head to head against semaglutide in a 210-person trial starting October 2026.
Three separate lawsuits against Novo Nordisk and Eli Lilly are working their way through the courts this week, while two new experimental GLP-1 drugs enter testing that could add fresh options in the years ahead. For patients using Ozempic or watching prices for these medications, the legal outcomes could affect both safety disclosures and what these drugs cost. Meanwhile, new trials testing orforglipron and zovaglutide suggest that weight loss and diabetes treatment options may keep expanding.
The Thompson case against Novo Nordisk centers on claims that the company overstated how much weight patients could expect to lose on Ozempic while downplaying risks tied to the drug. This kind of dispute matters because much of what patients know about a medication's real-world performance comes from company-sponsored studies and marketing materials, not independent review. If the court finds the claims credible, it could require Novo Nordisk to change how it communicates about Ozempic's benefits and risks going forward. The case has not reached a resolution, so nothing about current prescribing or labeling has changed yet, but patients weighing this drug may want to watch how the litigation develops.
A second lawsuit against Novo Nordisk, this one over pricing and marketing practices for its GLP-1 drugs, is also making its way through court. Drug pricing lawsuits like this one often examine whether a manufacturer's marketing claims justified the price it set, or whether patients and insurers paid more than they should have based on the benefits promised. Because GLP-1 drugs already carry a high sticker price for many patients without insurance coverage, any ruling here could influence what people ultimately pay at the pharmacy counter. The case is still active, so no changes to pricing have resulted yet, and it may be worth following for anyone budgeting for long-term GLP-1 treatment.
Eli Lilly is contending with its own legal challenge, a lawsuit from Fernandez alleging the company broke rules governing how GLP-1 drugs are marketed. Marketing rules for prescription drugs exist to make sure claims about benefits and risks are accurate and not misleading to patients or doctors. If the court sides with the plaintiff, Eli Lilly could face a settlement, or it could be required to revise the labeling on its GLP-1 products to better reflect approved claims. Neither outcome is guaranteed at this stage, since the case is still working through the legal process, but the result could shape how these drugs are promoted going forward.
Eli Lilly is also running a large Phase 3 trial of orforglipron, a GLP-1-like drug being tested in 2,000 adults who carry excess weight but have not yet developed diabetes or class 1 obesity. The goal of this study is to see whether the drug can stop that progression before it starts, rather than treating diabetes or obesity after they have already developed. This kind of prevention-focused research differs from most GLP-1 trials to date, which have mainly tested drugs in patients who already have a diagnosis. The trial is currently recruiting, so results are still years away, but the design points to where GLP-1 research may be headed next.
A newer entrant, zovaglutide, is set to begin a head-to-head trial against semaglutide in October 2026, enrolling 210 adults with obesity. Head-to-head trials like this one are designed to show how a new drug compares directly against an established one, rather than against a placebo, which gives a clearer picture of relative effectiveness and safety. Semaglutide, the active ingredient in Ozempic and Wegovy, has become the benchmark that newer GLP-1 candidates are measured against. If zovaglutide performs comparably or better, it could give patients and prescribers another option in a market still dominated by a small number of established drugs. The trial has not yet started recruiting, so any comparison remains speculative until results come in.
For patients currently using Ozempic, Wegovy, Mounjaro, or Zepbound, none of these lawsuits have changed what is approved or how these drugs should be prescribed today. I would suggest keeping an eye on the pricing and marketing cases if cost is a concern, since either could eventually affect what insurers and patients pay. At the same time, the arrival of orforglipron and zovaglutide in active trials is a reminder that today's GLP-1 options will likely look different in a few years. Readers weighing a decision now may want to discuss with their doctor whether waiting for new data makes sense for their situation, or whether moving ahead with an approved option fits their needs better.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.